Jeuveau, also known as prabotulinumtoxinA, is a recent addition to the neurotoxin market, gaining FDA approval in 2019.
Jeuveau, also known as prabotulinumtoxinA, is a recent addition to the neurotoxin market, gaining FDA approval in 2019. Unlike other neurotoxins, Jeuveau is specifically designed to target glabellar lines, the frown lines between the eyebrows.
Jeuveau is a type of botulinum toxin type A injection used to treat wrinkles. The FDA approved Jeuveau in February 2019 for this purpose.
Often called the “new Botox” or “Newtox,” Jeuveau has the same main ingredient as Botox Cosmetic.
Although Jeuveau is similar to Botox, it has a few differences. It works especially well for treating frown lines between the eyebrows (glabellar lines) and often costs a little less.
Jeuveau gives results similar to Botox and Dysport, lasting about 3 to 4 months. It smooths frown lines and helps the face look younger.
Before treatment, you should meet with a medical provider. They will check your face, decide how many units you need, and mark the areas to treat.
If you are new to toxin treatments, your provider may ask you to return in 2 weeks to check results.
Jeuveau treatments should be spaced at least 3 months apart. The effects are not permanent, and frown lines may return by the 3-month mark. If results fade too early, you may need a higher dose next time. Low doses often don’t last as long.
Following treatment, avoid rubbing or massaging the treated area for 24 hours. Refrain from strenuous exercise and excessive heat exposure for the first day post-injection.
